Shibahara Kotaro, Yamamoto Manabu, Kakeji Yoshihiro, Sakata Hisanobu, Maehara Yoshihiko
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Anticancer Res. 2008 May-Jun;28(3B):1779-83.
THE AIM of this study was to compare the efficacy and toxicity of S-1 to an oral combination regimen of tegafur and uracil (UFT) with leucovorin (LV) in metastatic colorectal carcinoma (CRC) patients.
Fifty-two patients were treated with either S-1 (80 mg/m2/d), administered for 28 days every 42 days, or UFT (300 mg/m2/d) and LV (90 mg/d), administered for 28 days every 35 days. The clinical results were compared retrospectively.
There were no statistically significant differences in overall response between the two patient groups. The overall response rate was 11.8% in the S-1 group, and 11.1% in the UFT/LV group. No statistically significant difference in-time- to progression (TTP) or survival time was observed between the treatments. The median survival time was 29 months with S-1 and 12 months with UFT/LV.
The oral S-1 provided similar safety and efficacy, compared to UFT/LV for metastatic CRC.
本研究的目的是比较S-1与替加氟尿嘧啶（UFT）联合亚叶酸钙（LV）口服方案对转移性结直肠癌（CRC）患者的疗效和毒性。
52例患者接受S-1（80mg/m²/天）治疗，每42天给药28天，或接受UFT（300mg/m²/天）和LV（90mg/天）治疗，每35天给药28天。对临床结果进行回顾性比较。
两组患者的总体缓解率无统计学显著差异。S-1组的总体缓解率为11.8%，UFT/LV组为11.1%。治疗之间未观察到进展时间（TTP）或生存时间的统计学显著差异。S-1治疗的中位生存时间为29个月，UFT/LV治疗为12个月。
与UFT/LV相比，口服S-1对转移性CRC具有相似的安全性和疗效。
